Introduction
============

Oral squamous cell carcinoma (OSCC) is the most frequently found oral neoplasm by a considerable margin, accounting for \~90% all types oral cancer ([@b1-ol-0-0-9647]). Due to a variety of factors, including a high degree of local invasiveness and metastasis to cervical lymph nodes ([@b2-ol-0-0-9647]), the survival rate of traditionally treated OSCC patients has improved slightly in the past three decades ([@b3-ol-0-0-9647],[@b4-ol-0-0-9647]). Regional or distant metastasis is one of the most crucial factors for the survival of patients. Therefore, searching for biomarkers associated with tumor progression has become a significant challenge in the diagnosis of OSCC ([@b5-ol-0-0-9647],[@b6-ol-0-0-9647]).

Proliferation marker protein Ki-67 (Ki-67), a nuclear and nucleolar protein, is expressed in proliferating cells from the G~1~ to the M phase of the cell cycle, with the exception of the resting phase G~0~ ([@b7-ol-0-0-9647]). A sharp decrease in Ki-67 levels occurs in later phases of mitosis ([@b8-ol-0-0-9647]). Additionally, Ki-67 has been shown to serve an important role in tumorigenesis due to its positive association with tumor proliferation and invasion ([@b9-ol-0-0-9647]), providing a marker of tumor aggressiveness.

Tumor cell proliferation is an important biological parameter for tumor diagnosis. High expression of Ki-67 in breast tumors shows higher proliferative and invasive activity ([@b10-ol-0-0-9647]). Kim *et al* found Ki-67 expression to be inversely associated with age and young age^/low^ Ki-67 patients (young age \<40 years, low Ki67 level \<10%) had significantly poorer recurrence-free survival (RFS) compared with older age^/high^ patients (old age ≥40 years, high Ki67 level ≥10%) with breast cancer ([@b10-ol-0-0-9647]). Another study showed that high Ki-67 expression was associated with good clinical outcomes and could act as a good independent prognostic marker in colorectal cancer ([@b11-ol-0-0-9647]). It was also reported that Ki-67, a proliferative marker, but not neuroendocrine expression, was an independent factor in predicting the prognosis of patients with prostate cancer ([@b12-ol-0-0-9647]). Furthermore, Ki-67 combined with other proteins can also be of diagnostic value. For example, certain studies found that a combination of B-cell lymphoma 2 protein and Ki-67 improved the detection of gastric cancer and identified metastatic castrate-resistant prostate cancer more accurately by assessing vimentin and Ki-67 expression ([@b13-ol-0-0-9647],[@b14-ol-0-0-9647]). Ki-67 was also reported to correlate with tumor progression in pancreatic neuroendocrine neoplasms ([@b15-ol-0-0-9647]).

Although Ki-67 has been reported to provide a diagnostic marker for neck metastasis in head and neck carcinomas ([@b16-ol-0-0-9647]), its role in OSCC has not been fully clarified. The present study aimed to evaluate the association between Ki-67 expression and the clinicopathological features of OSCC patients to further assess its diagnostic value.

Patients and methods
====================

### Patients and tissue specimens

Paraffin-embedded surgical tissues were randomly collected from 298 OSCC patients, 62 patients with oral leukoplakia exhibiting various histological grades of oral epithelial dysplasia and a control group (36 patients) with normal oral tissues. The specimens were collected from resection surgery at Nanjing Stomatological Hospital, Medical School of Nanjing University (Nanjing, China) between March 2007 and December 2014. Diagnosis was confirmed by postoperative pathology, and no patients received radiotherapy or chemotherapy prior to surgery. Pregnant patients and those diagnosed with other diseases were excluded from the present study. The approval of the Ethics Committee of the Stomatological Hospital Affiliated Medical School, Nanjing University was obtained, as was informed consent from the patients or their families. All patients were followed up bimonthly until July 31, 2015.

### Immunohistochemistry

Tissue specimens were fixed in 4% paraformaldehyde solution at 4°C for 24 h, paraffin-embedded, and then cut into 2-µm sections and placed on microscope slides for immunohistochemical analysis. In brief, the sections were successively incubated in xylene, 100% ethanol and 95% ethanol, blocked with 3% H~2~O~2~ for 10 min at room temperature and washed. A rabbit monoclonal antibody for Ki-67 (cat. no. ab15580; 1:200 dilution; Abcam, Cambridge, MA, USA) was incubated with all slides at 4°C overnight followed by use of the secondary antibody from the Dako Real™ Envision™ Detection System (cat. no. K500711; Dako; Agilent Technologies, Inc., Santa Clara, CA, USA), incubated at room temperature for 2 h. DAB (5 mg/ml) chromogen detection (EnVision Detection System; Agilent Technologies, Inc., Sana Clara, CA, USA) for 10 min was followed by nuclear staining using 1 mg/ml of hematoxylin for 2 min at room temperature. Samples were washed with tap water for 10 min, dehydrated, transparent, and detected with an inverted microscope (magnification, ×200 and ×400; Olympus CKX41; Olympus Corporation, Tokyo, Japan).

### Quantification of immunohistochemistry

Analysis and evaluation of immunostaining results was independently determined by two pathologists. Differences of opinion were reassessed together to reach consensus. Cells with brown staining under the microscope were considered as positive expression. The proportion of the number of Ki-67-positive cells to the number of total cells was recorded, and three different fields were examined within each micro-localization for the tumor specimen of each patient ([@b9-ol-0-0-9647]). The median proportion was used as a cutoff for further analysis of the Ki-67 high group (n=149) and the Ki-67 low group (n=149).

### Statistical analysis

SPSS version 16.0 (SPSS Inc., Chicago, IL, USA) and the Prism statistical software package version 6.0 (GraphPad Software Inc., San Diego, CA, USA) were used for statistical analyses. The χ^2^ test was used to compare the Ki67 high group and the Ki67 low group. Overall survival (OS), disease-free survival (DFS), recurrence-free survival (RFS) and metastasis-free survival (MFS) were estimated comparing high expression groups and low expression groups using Kaplan-Meier survival curves and the long-rank test. Survival time was defined as the interval between the date of surgery and the last date the patient was known to be disease-free or alive (censored). The Cox regression model was used to examine interactions between different prognostic factors in a multivariate analysis. Differences were considered statistically significant at P\<0.05.

Results
=======

### Ki-67 expression is associated with tumor progression

A total of 396 individuals (298 with OSCC, 62 with dysplasia and 36 with normal epithelia) were examined in the present study ([Table I](#tI-ol-0-0-9647){ref-type="table"}). Therefore, differences in Ki-67 expression by immunohistochemistry were analyzed from normal tissue to dysplasia and tumor tissues. It was found that Ki-67 expression was rare in normal oral mucosa and that its expression was mainly located in the basal cells, where it exhibited higher expression than that in normal mucosa ([Fig. 1](#f1-ol-0-0-9647){ref-type="fig"}). Ki-67 was highly expressed in the tumor tissues and was mainly expressed in the nuclei of tumor cells. The immunohistochemistry indicated that the Ki-67 high group with oral dysplasia of the epithelial mucosa accounted for 16.7% (n=33) of the total number of high Ki-67 expression cases, while the Ki-67 low group with oral dysplasia of the epithelial mucosa accounted for 14.6% (n=29) of the total number of cases with low Ki-67 expression ([Table I](#tI-ol-0-0-9647){ref-type="table"}).

As the dysplasia of oral epithelial mucosa included mild, moderate and severe dysplasia, Ki-67 expression was analyzed in these three types of tissues. The results showed that Ki-67 expression increased from mild dysplasia to moderate to severe, and demonstrated that the expression of Ki-67 increased with the decreased severity of oral leukoplakia: Mild dysplasia (n=9), 14.5%; moderate dysplasia (n=15), 24.2%; and severe dysplasia (n=38), 61.3% (P=0.029; [Table II](#tII-ol-0-0-9647){ref-type="table"}).

### Associations between Ki-67 expression and clinicopathological characteristics

The associations were investigated between Ki-67 expression and clinicopathological characteristics, including sex, age, smoking habits, Tumor-Node-Metastasis (TNM) stage ([@b17-ol-0-0-9647]), tumor differentiation, lymph node metastasis status, depth of tumor invasion (DOI) and worst pattern of invasion (WPOI) type ([@b18-ol-0-0-9647]). The results demonstrated that Ki-67 expression was significantly associated with patient age (P=0.011; [Table III](#tIII-ol-0-0-9647){ref-type="table"}), demonstrating that younger people (\<60 years) exhibited lower Ki-67 expression. Additionally, Ki-67 was highly expressed in patients with moderate-high differentiation (P=0.001; [Table III](#tIII-ol-0-0-9647){ref-type="table"}) and patients with lymph node metastasis (P=0.006; [Table III](#tIII-ol-0-0-9647){ref-type="table"}). In addition, Ki-67 expression was found to be higher in patients with WPOI types 4--5 than in those with types 1--3 (P\<0.0001; [Table III](#tIII-ol-0-0-9647){ref-type="table"}), but there was no significant difference between the DOI \<5 and ≥5 mm groups (P=0.082; [Table III](#tIII-ol-0-0-9647){ref-type="table"}).

### Associations between Ki-67 expression and survival time

Follow-up data was obtained and the association between Ki-67 expression and the clinical outcome of the patients was analyzed. All patients were separated into two groups according to Ki-67 expression using the median as the cutoff value. The association between OS, DFS, RFS, metastasis-free survival (MFS) and Ki-67 expression was then analyzed with Kaplan-Meier survival curves. The results demonstrated that higher Ki-67 expression was associated with poorer OS (P=0.035; [Fig. 2A](#f2-ol-0-0-9647){ref-type="fig"}), RFS (P=0.017; [Fig. 2B](#f2-ol-0-0-9647){ref-type="fig"}), MFS (P=0.032; [Fig. 2C](#f2-ol-0-0-9647){ref-type="fig"}) and DFS (P=0.018; [Fig. 2D](#f2-ol-0-0-9647){ref-type="fig"}) times. These results suggested that higher Ki-67 expression in OSCC patients was associated with an unsatisfactory clinical outcome.

### Ki-67 expression is an independent diagnostic marker for OSCC

Univariate analysis revealed that the following parameters were associated with increased mortality: TNM \[OS: Hazard ratio (HR), 0.081; 95% confidence interval (CI), 0.025--0.262; P\<0.0001; DFS: HR, 0.107; 95% CI, 0.033--0.345; P\<0.0001; RFS: HR, 0.106; 95% CI, 0.033--0.341; P\<0.0001; MFS: HR, 0.083; 95% CI, 0.025--0.267; P\<0.0001\], differentiation (OS: HR, 0.662; 95% CI, 0.521--0.842; P=0.001; DFS: HR, 0.724; 95% CI, 0.57--0.919; P=0.008; RFS: HR, 0.735; 95% CI, 0.579--0.933; P=0.011; MFS: HR, 0.652; 95% CI, 0.513--0.829; P\<0.0001) and Ki-67 expression (OS: HR, 1.893; 95% CI, 1.136--3.573; P=0.035; DFS: HR, 2.283; 95% CI, 1.408--3.766; P=0.018; RFS: HR, 2.43; 95% CI, 1.437--3.428; P=0.017; MFS: HR, 2.048; 95% CI, 1.165--3.393; P=0.032). In a further step of multivariate analysis, Ki-67 expression retained its negative impact on survival for OS, DFS, RFS and MFS ([Tables IV](#tIV-ol-0-0-9647){ref-type="table"}--[VII](#tVII-ol-0-0-9647){ref-type="table"}).

Discussion
==========

OSCC is among the most frequently diagnosed cancer types worldwide. However, despite improved therapies, the 5-year survival rate has not changed. Overall, \>50% of patients with OSCC demonstrate regional and distant metastases, which result in treatment failures and occasionally mortality within a year due to recurrent or metastatic disease ([@b19-ol-0-0-9647],[@b20-ol-0-0-9647]). In order to improve the survival rate for OSCC, identification of an underlying molecular event differentiating patients at risk for progression at the premalignant stage, is required ([@b21-ol-0-0-9647]). Factors, including tumor size, lymph node metastasis, TNM type and differentiation, influence the prognosis of OSCC ([@b22-ol-0-0-9647]).

Ki-67 is an indicator of cell proliferation and has been shown to be upregulated in numerous tumors ([@b23-ol-0-0-9647],[@b24-ol-0-0-9647]). Tumor proliferative activity labeled by Ki-67 has been found to be associated with tumor aggression, which is specified by tumor grade and stage. Several studies have described these associations and identified Ki-67 as a prognostic factor ([@b14-ol-0-0-9647],[@b25-ol-0-0-9647]--[@b27-ol-0-0-9647]). The present study found upregulation of Ki-67 expression with tumor progression using normal epithelial mucosa, dysplasia and OSCC samples. In addition, Ki-67 expression also increased from mild to moderate to severe dysplasia. Another important finding was that high expression of Ki-67 was associated with severe differentiation (P=0.001), lymph node metastasis (P=0.006) and higher WPOI (P\<0.0001). Furthermore, high Ki-67 expression was significantly associated with poor survival time with regards to OS (P=0.035), RFS (P=0.017), MFS (P=0.032) and DFS (P=0.018). The biological behavior of OSCC with highly expressed Ki-67 is verified by the association between Ki-67 and affiliated potential clinicopathological characteristics; for example, differentiation, lymph node metastasis, TNM, DOI and WPOI. Unexpectedly, the multivariate analysis revealed that Ki-67 could be an independent predictor for OS, RFS, MFS and RFS.

In summary, the findings of the present study strongly argue for the value of highly expressed Ki-67 as an independent prognostic marker for OSCC. Considering the extensive heterogeneity of tumors, further researches need to enrich correlations of spatial expression of Ki67 with OSCC.
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###### 

Ki-67 expression in normal mucosa, oral epithelial dysplasia and OSCC samples.

                              Ki-67 expression                                     
  --------------------------- ------------------ ------------ ------------ ------- -------
  Normal oral mucosa          36 (9.0)           20 (10.1)    16 (8.0)     2.828   0.568
  Oral epithelial dysplasia   62 (15.7)          29 (14.6)    33 (16.7)            
  OSCC                        298 (75.3)         149 (75.3)   149 (75.3)           

Ki-67, proliferation marker protein Ki-67; OSCC, oral squamous cell carcinoma.

###### 

Associations between Ki-67 expression and various grades of oral epithelial dysplasia.

                         Ki-67 expression                       
  ---------- ----------- ------------------ ----------- ------- ----------------------------------------------------
  Mild       9 (14.5)    3 (33.3)           6 (66.7)    7.685   0.029^[a](#tfn2-ol-0-0-9647){ref-type="table-fn"}^
  Moderate   15 (24.2)   4 (26.7)           11 (73.3)           
  Severe     38 (61.3)   15 (39.5)          23 (60.5)           

P\<0.05. Ki-67, proliferation marker protein Ki-67.

###### 

Ki-67 expression ratio and clinicopathological characteristics in patients with oral squamous cell carcinoma.

                                                       Ki-67 expression                         
  ----------------------- --------------- ------------ ------------------ ------------ -------- -------------------------------------------------------
  Sex                     Male            152 (51)     72 (48.3)          80 (53.7)    0.859    0.354
                          Female          146 (49)     77 (51.7)          69 (46.3)             
  Age                     \<60 years      138 (46.3)   80 (53.7)          58 (38.9)    6.532    0.011^[a](#tfn3-ol-0-0-9647){ref-type="table-fn"}^
                          ≥60 years       160 (53.7)   69 (46.3)          91 (61.1)             
  TNM                     I--III          295 (99)     148 (99.3)         147 (98.7)   0.337    0.562
                          IV--V           3 (1)        1 (0.7)            2 (1.3)               
  Differentiation         Low             149 (50)     89 (59.7)          60 (40.3)    11.289   0.001^[a](#tfn3-ol-0-0-9647){ref-type="table-fn"}^
                          Moderate-high   149 (50)     60 (40.3)          89 (59.7)             
  Lymph node metastasis   Yes             11 (3.7)     1 (0.7)            10 (6.7)     7.646    0.006^[a](#tfn3-ol-0-0-9647){ref-type="table-fn"}^
                          No              287 (96.3)   148 (99.3)         139 (93.3)            
  Depth of invasion       \<5 mm          143 (48)     79 (53)            64 (43)      3.025    0.082
                          ≥5 mm           155 (52)     70 (47)            85 (57)               
  WPOI                    I--III          174 (58.4)   103 (69.1)         71 (47.7)    14.143   \<0.0001^[a](#tfn3-ol-0-0-9647){ref-type="table-fn"}^
                          IV--V           124 (41.6)   46 (30.9)          78 (52.3)             

P\<0.05. Ki-67, proliferation marker protein Ki-67; TNM, Tumor-Node-Metastasis; WPOI, worst pattern of invasion.

###### 

Prognostic factors in the Cox proportional hazards model for overall survival.

                                                    Univariate   Multivariate                                                                                  
  ----------------------- ------------------------- ------------ -------------- ------------------------------------------------------- ------- -------------- -------------------------------------------------------
  Sex                     Male vs. female           1.138        0.899--1.442   0.281                                                   1.114   0.877--1.414   0.378
  Age                     \<60 vs. ≥60 years        1.208        0.953--1.53    0.118                                                   1.154   0.906--1.469   0.246
  TNM                     I--III vs. IV--V          0.081        0.025--0.262   \<0.0001^[a](#tfn4-ol-0-0-9647){ref-type="table-fn"}^   0.08    0.024--0.264   \<0.0001^[a](#tfn4-ol-0-0-9647){ref-type="table-fn"}^
  Differentiation         Low vs. moderate-high     0.662        0.521--0.842   0.001^[a](#tfn4-ol-0-0-9647){ref-type="table-fn"}^      0.659   0.507--0.858   0.002^[a](#tfn4-ol-0-0-9647){ref-type="table-fn"}^
  Lymph node metastasis   Yes vs. no                1.003        0.372--2.704   0.996                                                   1.159   0.425--3.162   0.773
  Depth of invasion       \<5 vs. ≥5 mm             1.011        0.798--1.28    0.929                                                   1.137   0.879--1.47    0.329
  WPOI                    I--III vs. IV--V          0.912        0.715--1.164   0.461                                                   1.015   0.776--1.326   0.915
  Ki-67                   Low vs. high expression   1.893        1.136--3.573   0.035^[a](#tfn4-ol-0-0-9647){ref-type="table-fn"}^      1.261   1.051--3.287   0.044^[a](#tfn4-ol-0-0-9647){ref-type="table-fn"}^

P\<0.05. HR, hazard ratio; CI, confidence interval; TNM, Tumor-Node-Metastasis; WPOI, worst pattern of invasion; Ki-67, proliferation marker protein Ki-67.

###### 

Prognostic factors in the Cox proportional hazards model for disease-free survival.

                                                    Univariate   Multivariate                                                                                  
  ----------------------- ------------------------- ------------ -------------- ------------------------------------------------------- ------- -------------- -------------------------------------------------------
  Sex                     Male vs. female           1.15         0.916--1.467   0.220                                                   1.136   0.896--1.442   0.292
  Age                     \<60 vs. ≥60 years        1.135        0.896--1.438   0.293                                                   1.103   0.867--1.403   0.426
  TNM                     I--III vs. IV--V          0.107        0.033--0.345   \<0.0001^[a](#tfn5-ol-0-0-9647){ref-type="table-fn"}^   0.1     0.031--0.327   \<0.0001^[a](#tfn5-ol-0-0-9647){ref-type="table-fn"}^
  Differentiation         Low vs. moderate-high     0.724        0.57--0.919    0.008^[a](#tfn5-ol-0-0-9647){ref-type="table-fn"}^      0.737   0.568--0.957   0.022^[a](#tfn5-ol-0-0-9647){ref-type="table-fn"}^
  Lymph node metastasis   Yes vs. no                0.572        0.209--1.561   0.276                                                   0.592   0.215--1.631   0.311
  Depth of invasion       \<5 vs. ≥5 mm             1.009        0.797--1.277   0.943                                                   1.123   0.872--1.448   0.369
  WPOI                    I--III vs. IV--V          0.88         0.69--1.121    0.301                                                   0.961   0.738--1.252   0.769
  Ki-67                   Low vs. high expression   2.283        1.408--3.766   0.018^[a](#tfn5-ol-0-0-9647){ref-type="table-fn"}^      1.828   1.056--3.149   0.043^[a](#tfn5-ol-0-0-9647){ref-type="table-fn"}^

P\<0.05. HR, hazard ratio; CI, confidence interval; TNM, Tumor-Node-Metastasis; WPOI, worst pattern of invasion; Ki-67, proliferation marker protein Ki-67.

###### 

Prognostic factors in the Cox proportional hazards model for recurrence-free survival.

                                                    Univariate   Multivariate                                                                                  
  ----------------------- ------------------------- ------------ -------------- ------------------------------------------------------- ------- -------------- -------------------------------------------------------
  Sex                     Male vs. female           1.143        0.903--1.448   0.265                                                   1.127   0.888--1.431   0.327
  Age                     \<60 vs. ≥60 years        1.122        0.886--1.422   0.340                                                   1.083   0.851--1.378   0.516
  TNM                     I--III vs. IV--V          0.106        0.033--0.341   \<0.0001^[a](#tfn6-ol-0-0-9647){ref-type="table-fn"}^   0.102   0.031--0.333   \<0.0001^[a](#tfn6-ol-0-0-9647){ref-type="table-fn"}^
  Differentiation         Low vs. moderate-high     0.735        0.579--0.933   0.011^[a](#tfn6-ol-0-0-9647){ref-type="table-fn"}^      0.736   0.567--0.956   0.022^[a](#tfn6-ol-0-0-9647){ref-type="table-fn"}^
  Lymph node metastasis   Yes vs. no                1.088        0.404--2.932   0.868                                                   1.227   0.45--3.345    0.690
  Depth of invasion       \<5 vs. ≥5 mm             1.023        0.808--1.296   0.848                                                   1.139   0.884--1.47    0.314
  WPOI                    I--III vs. IV--V          0.897        0.703--1.143   0.378                                                   0.962   0.738--1.254   0.774
  Ki-67                   Low vs. high expression   2.43         1.437--3.428   0.017^[a](#tfn6-ol-0-0-9647){ref-type="table-fn"}^      2.461   1.308--4.571   0.024^[a](#tfn6-ol-0-0-9647){ref-type="table-fn"}^

P\<0.05. HR, hazard ratio; CI, confidence interval; TNM, Tumor-Node-Metastasis; WPOI, worst pattern of invasion; Ki-67, proliferation marker protein Ki-67.

###### 

Prognostic factors in the Cox proportional hazards model for metastasis-free survival.

                                                    Univariate   Multivariate                                                                                   
  ----------------------- ------------------------- ------------ -------------- ------------------------------------------------------- ------- --------------- -------------------------------------------------------
  Sex                     Male vs. female           1.152        0.91--1.459    0.239                                                   1.123   0.885--1.425    0.340
  Age                     \<60 vs. ≥60 years        1.223        0.965--1.549   0.096                                                   1.178   0.925--1.5      0.185
  TNM                     I--III vs. IV--V          0.083        0.025--0.267   \<0.0001^[a](#tfn7-ol-0-0-9647){ref-type="table-fn"}^   0.078   0.024--0.258    \<0.0001^[a](#tfn7-ol-0-0-9647){ref-type="table-fn"}^
  Differentiation         Low vs. moderate-high     0.652        0.513--0.829   \<0.0001^[a](#tfn7-ol-0-0-9647){ref-type="table-fn"}^   0.66    0.508--0.858    0.002^[a](#tfn7-ol-0-0-9647){ref-type="table-fn"}^
  Lymph node metastasis   Yes vs. no                0.498        0.182--1.363   0.175                                                   0.506   0.183--1.398    0.189
  Depth of invasion       \<5 vs. ≥5 mm             0.997        0.787--1.263   0.979                                                   1.119   0.866--1.446    0.390
  WPOI                    I--III vs. IV--V          0.896        0.703--1.143   0.377                                                   1.015   0.777--1.325    0.916
  Ki-67                   Low vs. high expression   2.048        1.165--3.393   0.032^[a](#tfn7-ol-0-0-9647){ref-type="table-fn"}^      3.301   1.077--10.116   0.037^[a](#tfn7-ol-0-0-9647){ref-type="table-fn"}^

P\<0.05. HR, hazard ratio; CI, confidence interval; TNM, Tumor-Node-Metastasis; WPOI, worst pattern of invasion; Ki-67, proliferation marker protein Ki-67.
